Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 3.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 89,626 shares of the company’s stock after selling 2,782 shares during the period. Charles Schwab Investment Management Inc. owned 0.12% of Kiniksa Pharmaceuticals worth $2,240,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in KNSA. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares during the period. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after acquiring an additional 223,094 shares during the period. Dimensional Fund Advisors LP grew its position in Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after acquiring an additional 157,741 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in Kiniksa Pharmaceuticals during the third quarter valued at about $2,438,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Kiniksa Pharmaceuticals by 40.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock valued at $8,098,000 after acquiring an additional 92,985 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling

In related news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,592 shares of company stock valued at $1,110,364. Insiders own 54.57% of the company’s stock.

Analyst Ratings Changes

KNSA has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Stock Up 0.3 %

NASDAQ:KNSA opened at $20.20 on Monday. The business’s 50 day moving average is $23.25 and its two-hundred day moving average is $23.10. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The company has a market cap of $1.46 billion, a PE ratio of -144.29 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s quarterly revenue was up 67.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) EPS. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.